publication venue for
- Overexpression of KCNN4 channels in principal neurons produces an anti-seizure effect without reducing their coding ability. 2023
- The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies.. 22. 2014
- Preservation of forelimb function by UPF1 gene therapy in a rat model of TDP-43-induced motor paralysis.. 22. 2014
- Virus-mimetic polyplex particles for systemic and inflammation-specific targeted delivery of large genetic contents.. 20. 2013
- Reprogramming axonal behavior by axon-specific viral transduction.. 19. 2012
- Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia.. 19. 2011
- Transfection of shRNA-encoding Minivector DNA of a few hundred base pairs to regulate gene expression in lymphoma cells.. 18. 2010
- AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors.. 17. 2010
- Affinity maturation of an anti-V antigen IgG expressed in situ through adenovirus gene delivery confers enhanced protection against Yersinia pestis challenge.. 17. 2010
- Genetically engineered Newcastle disease virus for malignant melanoma therapy.. 16. 2009
- Quantitative analysis of clinically relevant mutations occurring in lymphoid cells harboring gamma-retrovirus-encoded hsvtk suicide genes.. 15. 2008
- Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer.. 14. 2006
- Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in cell factories.. 13. 2006
- AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL.. 12. 2005
- Adenovirus-based vascular endothelial growth factor gene delivery to human pancreatic islets.. 11. 2004
- Insertional oncogenesis in gene therapy: how much of a risk?. 11. 2004
- Discordant effects of a soluble VEGF receptor on wound healing and angiogenesis.. 11. 2004
- Bone marrow-derived, endothelial progenitor-like cells as angiogenesis-selective gene-targeting vectors.. 10. 2003
- Recombinant angiostatin prevents retinal neovascularization in a murine proliferative retinopathy model.. 8. 2001
- Replication and cytolysis of an E1B-attenuated adenovirus in drug-resistant ovarian tumour cells is associated with reduced apoptosis.. 8. 2001
- Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen.. 7. 2000
- Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status.. 7. 2000
- Lipid-mediated gene transfer of viral IL-10 prolongs vascularized cardiac allograft survival by inhibiting donor-specific cellular and humoral immune responses.. 5. 1998
- Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma.. 5. 1998
- In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector.. 5. 1998
- Adenovirus facilitated infection of human cells with ecotropic retrovirus.. 5. 1998
- Regional 'pro-drug' gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma.. 5. 1998
- The effect of mucolytic agents on gene transfer across a CF sputum barrier in vitro.. 5. 1998
- Ability of a chimeric cAMP-responsive promoter to confer pharmacologic control of CFTR cDNA expression and cAMP-mediated Cl- secretion.. 4. 1997
- The internal ribosomal entry site of the encephalomyocarditis virus enables reliable coexpression of two transgenes in human primary T lymphocytes.. 4. 1997
- Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome P450 2B1 gene together with cyclophosphamide.. 3. 1996
- Circumventing the immune response to adenovirus-mediated gene therapy.. 3. 1996
- Safety and efficacy of in vivo gene transfer into the porcine heart with replication-deficient, recombinant adenovirus vectors.. 3. 1996
- Modulation of gene expression after replication-deficient, recombinant adenovirus-mediated gene transfer by the product of a second adenovirus vector.. 2. 1995
- The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer.. 1. 1994
- B-50/GAP-43 expression via a defective herpes simplex virus vector results in persistent morphological changes in non-neuronal cells.. 1 Suppl 1. 1994
- Immuno gene therapy comes into its own.. 4. 1997
- Progress and prospects: gene therapy for performance and appearance enhancement. 2008
- Progress and prospects: gene therapy clinical trials (part 1). 2007
- Efficient mobilization and recruitment of marrow-derived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors. 2002